Markers of immunogenic tumor cell death alone are not likely to be sufficient, insofar as HMGB1 release occurs in CPA-treated B16F10 tumors [13], which we found are largely immune unresponsive to CPA/6d treatment. Here, HMGB1 is linked to neoplasm.